Inclusion Criteria:

• Histologically or cytologically proven squamous cell carcinoma of the head and neck (SCCHN) at stage II, III, and IV, without evidence of distant metastasis
• Primary tumor sites eligible: nasopharyngeal, oropharynx, hypopharynx or larynx. Tumors of the nasal and paranasal cavities will also be included. Unknkown primary squamous cell carcinoma in the neck will also be eligible;
• Completed radiation therapy, beginning 8-12 weeks, up to 20 weeks;
• No measurable, persistent, or recurrent tumor that is ascertained by a formal restaging process by the study team
• Currently or recently undergoing swallowing therapy program with or without feeding tube use, with or without neck dissection;
• Age >= 18 years;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• Adequate hematological function: neutrophil count > 1.0x10^9/L, platelet count > 50x10^9/L;
• Signed informed consent.

Exclusion Criteria:

Patients with the following criteria will NOT be eligible for the study:

• SCCHN patients with tumor site at oral cavity
• SCCHN patients enrolled in other investigational trials
• Unstable cardiac disease or myocardial infarction within 6 months prior to study entry;
• Wearing a pacemaker or implantable cardioverter-defibrillator;
• History of significant neurologic disorder that affects swallowing, including stroke, neurodegenerative disease, advanced dementia, or uncontrolled seizure disorder;
• Active clinically significant uncontrolled infection;
• Prior use of acupuncture for dysphagia